INTRODUCTION {#s1}
============

Continuous and rapid advances in tumor biology, drug discovery and immunotherapy are accelerating the adoption of precision oncology. There is a growing arsenal of targeted therapeutics that disrupt oncogenes and modulate dysregulated molecular pathways \[[@R1]\]. Additionally, a growing subclass of molecularly targeted immunotherapeutics has developed to either stimulate or reduce the inhibition of cytotoxic T-cells \[[@R2]--[@R4]\]. Adoptive T-cell engineering, including chimeric antigen receptor T-cells (CAR-T), is being used to precisely target cancer cells that express specific antigens \[[@R5], [@R6]\]. Oncolytic viruses are also being engineered to target molecular states of tumor cells \[[@R7]\]. This rapid pace of development has led to a large menu of genomic and transcriptomic alterations that are potentially clinically-relevant for each individual patient. Therefore, well-designed genomic and transcriptomic sequencing panels are necessary for clinical testing \[[@R1]\].

We previously presented the Tempus xO assay, a next generation sequencing (NGS)-based oncology assay that interrogates 1,711 cancer-related genes in matched tumor and normal tissue with whole transcriptome RNA sequencing (RNA-seq) for gene rearrangement detection \[[@R8]\]. We now present the Tempus xT assay, a more focused targeted oncology panel using hybrid capture NGS to interrogate a refined list of 595 genes (Table [1](#T1){ref-type="table"}), including solid tumor and hematologic malignancy targets selected through extensive review of recent literature and oncogenic pathway analysis (see Methods). The assay also includes a combination of whole transcriptome RNA-Seq and targeted DNA tiling probes (Table [2](#T2){ref-type="table"}) for comprehensive gene rearrangement detection, as well as microsatellite instability (MSI) testing. In addition to the clinical testing function of the assay, the DNA- and RNA-seq assay components support a combination of research and clinical tools for the evaluation of tumor immunity status, including HLA typing, neoantigen prediction, DNA repair gene analysis, MSI status, tumor mutational burden, and immune cell typing and expression.

###### xT gene list

  ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  ABCB1      ABCC3      ABL1       ABL2       ACTA2      ACVR1B     AJUBA      AKT1       AKT2       AKT3       ALK
  AMER1      APC        APOB       AR         ARAF       ARHGAP26   ARHGAP35   ARID1A     ARID1B     ARID2      ARID5B
  ASNS       ASXL1      ATIC       ATM        ATP7B      ATR        ATRX       AURKA      AURKB      AXIN1      AXIN2
  AXL        B2M        BAP1       BARD1      BCL2       BCL2L1     BCL2L11    BCL6       BCL7A      BCL10      BCL11B
  BCLAF1     BCOR       BCORL1     BCR        BIRC3      BLM        BMPR1A     BRAF       BRCA1      BRCA2      BRD4
  BRIP1      BTG1       BTK        BUB1B      C3orf70    C8orf34    C10orf54   C11orf30   C11orf65   CALR       CARD11
  CASP8      CASR       CBFB       CBL        CBLB       CBLC       CBR3       CCDC6      CCND1      CCND2      CCND3
  CCNE1      CD19       CD22       CD40       CD70       CD79A      CD79B      CD274      CDC73      CDH1       CDK4
  CDK6       CDK8       CDK12      CDKN1A     CDKN1B     CDKN1C     CDKN2A     CDKN2B     CDKN2C     CEBPA      CEP57
  CFTR       CHD2       CHD4       CHEK1      CHEK2      CIC        CIITA      CKS1B      CREBBP     CRKL       CRLF2
  CSF1R      CSF3R      CTC1       CTCF       CTLA4      CTNNA1     CTNNB1     CTRC       CUX1       CXCR4      CYLD
  CYP1B1     CYP2D6     CYP3A5     DAXX       DDB2       DDR2       DDX3X      DICER1     DIRC2      DIS3       DIS3L2
  DKC1       DNM2       DNMT3A     DOT1L      DPYD       DYNC2H1    EBF1       ECT2L      EGF        EGFR       EGLN1
  ELF3       ENG        EP300      EPCAM      EPHA2      EPHA7      EPHB1      EPHB2      EPOR       ERBB2      ERBB3
  ERBB4      ERCC1      ERCC2      ERCC3      ERCC4      ERCC5      ERCC6      ERG        ERRFI1     ESR1       ETS1
  ETS2       ETV1       ETV4       ETV5       ETV6       EWSR1      EZH2       FAM46C     FAM175A    FANCA      FANCB
  FANCC      FANCD2     FANCE      FANCF      FANCG      FANCI      FANCL      FANCM      FAS        FAT1       FBXO11
  FBXW7      FCGR2A     FCGR3A     FDPS       FGF1       FGF2       FGF3       FGF4       FGF5       FGF6       FGF7
  FGF8       FGF9       FGF10      FGF14      FGF23      FGFR1      FGFR2      FGFR3      FGFR4      FH         FHIT
  FLCN       FLG        FLT1       FLT3       FLT4       FNTB       FOXA1      FOXL2      FOXO1      FOXO3      FOXP1
  FOXQ1      FRS2       FUBP1      G6PD       GALNT12    GATA1      GATA2      GATA3      GATA4      GATA6      GEN1
  GLI1       GNA11      GNA13      GNAQ       GNAS       GPC3       GPS2       GREM1      GRIN2A     GRM3       GSTP1
  H3F3A      H19        HAS3       HAVCR2     HDAC1      HDAC2      HDAC4      HGF        HIF1A      HIST1H1E   HIST1H3B
  HIST1H4E   HLA-A      HLA-B      HLA-C      HLA-DMA    HLA-DMB    HLA-DOA    HLA-DOB    HLA-DPA1   HLA-DPB1   HLA-DPB2
  HLA-DQA1   HLA-DQA2   HLA-DQB1   HLA-DQB2   HLA-DRA    HLA-DRB1   HLA-DRB5   HLA-DRB6   HLA-E      HLA-F      HLA-G
  HNF1A      HNF1B      HOXB13     HRAS       HSP90AA1   HSPH1      IDH1       IDH2       IDO1       IFIT1      IFIT2
  IFIT3      IFNAR1     IFNAR2     IFNGR1     IFNGR2     IFNL3      IKBKE      IKZF1      IL2RA      IL6R       IL7R
  IL10RA     IL15       ING1       INPP4B     IRF1       IRF2       IRF4       IRS2       ITPKB      JAK1       JAK2
  JAK3       JUN        KAT6A      KDM5A      KDM5C      KDM6A      KDR        KEAP1      KEL        KIF1B      KIT
  KLHL6      KLLN       KMT2A      KMT2B      KMT2C      KMT2D      KRAS       LAG3       LDLR       LEF1       LMNA
  LMO1       LRP1B      LYN        LZTR1      MAD2L2     MAF        MAFB       MALT1      MAP2K1     MAP2K2     MAP2K4
  MAP3K1     MAP3K7     MAPK1      MAX        MC1R       MCL1       MDM2       MDM4       MED12      MEF2B      MEN1
  MET        MGMT       MIB1       MITF       MKI67      MLH1       MLH3       MLLT3      MPL        MRE11A     MS4A1
  MSH2       MSH3       MSH6       MTAP       MTHFR      MTOR       MTRR       MUTYH      MYB        MYC        MYCL
  MYCN       MYD88      MYH11      NBN        NCOR1      NCOR2      NF1        NF2        NFE2L2     NFKBIA     NHP2
  NKX2-1     NOP10      NOTCH1     NOTCH2     NOTCH3     NPM1       NQO1       NRAS       NRG1       NSD1       NT5C2
  NTHL1      NTRK1      NTRK2      NTRK3      NUDT15     NUP98      P2RY8      PAK1       PALB2      PALLD      PARK2
  PAX3       PAX5       PAX7       PAX8       PBRM1      PCBP1      PDCD1      PDCD1LG2   PDGFRA     PDGFRB     PDK1
  PDPK1      PHF6       PHOX2B     PIAS4      PIK3C2B    PIK3CA     PIK3CB     PIK3CD     PIK3CG     PIK3R1     PIK3R2
  PIM1       PLCG2      PML        PMS1       PMS2       POLD1      POLE       POLH       POT1       POU2F2     PPP1R15A
  PPP2R1A    PPP2R2A    PPP6C      PRCC       PRDM1      PREX2      PRKAR1A    PRSS1      PRSS2      PTCH1      PTCH2
  PTEN       PTPN11     PTPN13     PTPN22     PTPRD      QKI        RAC1       RAD21      RAD50      RAD51      RAD51B
  RAD51C     RAD51D     RAD54L     RAF1       RANBP2     RARA       RASA1      RB1        RBM10      RECQL4     RET
  RHOA       RICTOR     RINT1      RIT1       RNF43      RNF139     ROS1       RPL5       RPS6KB1    RPS15      RPTOR
  RSF1       RUNX1      RUNX1T1    RXRA       SCG5       SDHA       SDHAF2     SDHB       SDHC       SDHD       SEC23B
  SEMA3C     SETBP1     SETD2      SF3B1      SGK1       SH2B3      SLC26A3    SLC47A2    SLIT2      SLX4       SMAD2
  SMAD3      SMAD4      SMARCA1    SMARCA4    SMARCB1    SMARCE1    SMC1A      SMC3       SMO        SOCS1      SOD2
  SOX2       SOX9       SOX10      SPEN       SPINK1     SPOP       SPRED1     SRC        SRSF2      STAG2      STAT3
  STAT4      STAT5A     STAT5B     STAT6      STK11      SUFU       SUZ12      SYK        TAF1       TANC1      TAP1
  TAP2       TBC1D12    TBL1XR1    TBX3       TCF3       TCF7L2     TCL1A      TERT       TET2       TGFBR2     TIGIT
  TMEM127    TMEM173    TMPRSS2    TNF        TNFAIP3    TNFRSF9    TNFRSF14   TNFRSF17   TOP1       TOP2A      TP53
  TP63       TPM1       TPMT       TRAF3      TSC1       TSC2       TSHR       TUSC3      TYMS       U2AF1      UBE2T
  UGT1A1     UGT1A9     UMPS       VEGFA      VHL        WEE1       WHSC1      WRN        WT1        XPA        XPC
  XPO1       XRCC1      XRCC2      XRCC3      YEATS4     ZFHX3      ZNF217     ZNF471     ZNF620     ZNF750     ZNRF3
  ZRSR2                                                                                                         
  ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------

###### DNA gene rearrangement regions

  Gene      xT DNA-seq detected regions
  --------- --------------------------------------------
  ABL1      5′UTR, introns 1, 2
  ALK       introns 18, 19, 20
  BCR       promoter, UTR, introns 1 through 22
  BRAF      introns 8, 9, 10
  EGFR      introns 23, 24, 25, 26, 27
  ETV6      introns 4, 5
  EWSRl     promoter, UTR, introns 1 through 16
  FGFR2     5′UTR, introns 1 through 17
  FGFR3     Full gene
  MYB       Full gene
  MYC       Full gene
  NRGl      introns 3, 5
  NTRKl     introns 9, 10, 11, 12, 13, 14, 15, 16
  NTRK3     introns 13, 14
  PAX8      Full gene
  PDGFRA    intron 11
  PML       introns 3, 4, 5, 6, 7, 8
  RARA      intron 2
  RET       introns 6, 7, 8, 9, 10, 11, 12
  ROSI      introns 31, 32, 33, 34, 35, 36, 37, 38, 39
  TMPRSS2   UTR, introns 2, 3, 4, 5

RESULTS {#s2}
=======

We have instituted performance benchmarks to support the clinical use of the xT assay and have assessed analytical sensitivity, specificity, accuracy and precision across the test\'s reportable range.

Single nucleotide variant and indel sensitivity, specificity, and limit of detection {#s2_1}
------------------------------------------------------------------------------------

In order to determine assay sensitivity for single nucleotide variants (SNVs) in solid tumors, a panel of formalin-fixed, paraffin-embedded (FFPE) clinical tumor samples were sequenced and compared against previously reported results from the Tempus xO assay \[[@R8]\]. There were 487 unique SNVs previously detected in the tumor samples, with variant allele fractions (VAFs) from 5% to 100% (median 25.9%). All but four variants were detected in both assays, resulting in a SNV sensitivity of 99.1% (354/357). To categorize sensitivity at low VAFs, reference standards containing variants between 1-30% VAF were used (Horizon Diagnostics, Columbus, GA). This comparison showed a sensitivity of 96.9% (126/130).

Specificity was calculated as the number of bases identified as negative for variation by both the xT assay and orthogonal methodology, divided by the total number of bases called negative by the assay. A total of two false positives were observed resulting in a specificity of \>99.9%, with a positive predictive value (PPV) of 99.5% (347/349). The overall precision of the assay was calculated as 97.2%, with a slight dependency on base fraction at the lower limit of detection (LOD) (Figure [1A, 1B](#F1){ref-type="fig"}). Additionally, the correlation of VAF measurements between the xT and xO assays was determined by measuring the correlation coefficient (Figure [1C, 1D](#F1){ref-type="fig"}). The xT assay shows high concordance in base fractions (r^2^ = 0.971 for indels, r^2^ = 0.921 for SNVs) with the xO assay at all ranges of performance.

![Performance of SNV and Indel Detection by the Tempus xT assay\
(**A**) Precision of indel detection by VAF. Precision was calculated for each bin of variants with allele fractions rounded to the nearest 5 percent. The vertical black line corresponds to the LOD. (**B**) Precision of SNV detection by VAF, as in A. (**C**) Correlation of xT assay indel VAFs to xO assay indel VAFs. (**D**) Correlation of xT assay SNV VAFs to xO assay SNV VAFs. (**E**) VAFs of indels and SNVs detected on chromosome 17 in four samples with serial 1:1 dilutions of the xT assay. Dark blue lines indicate best fit of a linear model. (**F**) Positive control detection. Boxplots of the VAF of three SNVs in a positive control sample run on every xT assay over a period of 5 months. The single point marked in black is an *AKT1* p.E17K variant which failed filtering criteria.](oncotarget-10-2384-g001){#F1}

Serial dilution of tumor samples with matched normal samples was performed to generate variants with base fractions between 25% and 1% VAF. Three variants were detected using dilutions down to 1.4% VAF (1:16 dilution of a 20% variant in the tumor). One mutation was detected down to an allele fraction of 2.1% (1:8 dilution) but not at the 1:16 dilution (Figure [1E](#F1){ref-type="fig"}). A conservative LOD of 5% was therefore set for SNVs, although we observed consistent detection below that threshold (Figure [1F](#F1){ref-type="fig"}).

Indels were consistently detected down to 4% VAF (Figure [1E](#F1){ref-type="fig"}). A conservative LOD of 10% was therefore set for the indels. Fifty indels were called within the xT LOD for 48 samples in the set. Of these 50 indels, 48 were called by xT, and one variant (*NOTCH3* p.1317fs) was excluded from analysis due to insufficient coverage on the xT panel. Thus, the final sensitivity calculation was 98.0% (48/49). PPV was calculated using the 49 indels called by the xT assay and their comparison against all xO data. All 49 indels called were concordant with the xO assay. We, therefore, observed a \>99.9% PPV for indel detection.

Gene rearrangement and fusion validation {#s2_2}
----------------------------------------

The assay is designed to assess 21 gene rearrangement targets by DNA-seq (Table [2](#T2){ref-type="table"}), in addition to comprehensive fusion detection by RNA-seq as previously reported \[[@R8]\]. The reportable range for gene rearrangements by DNA-seq is limited to fusions occurring in the specific regions listed in Table [2](#T2){ref-type="table"}. Twenty-seven validation samples (including 23 patient samples and 4 reference standards) with known gene rearrangements were sequenced. Results were compared with the previously validated RNA-seq fusion detection assay \[[@R8]\], and the reference standard results were compared with the manufacturer-provided data sheets. The assay successfully detected 28 of the 29 gene rearrangements within the 27 samples. The DNA-seq translocation detection sensitivity was 96.5% (28/29), with an overall sensitivity of translocation detection, including RNA-seq, of 99.9% (29/29). The overall distribution of reported gene rearrangements by cancer type for the patient cohort sequenced at Tempus Labs is shown in Figure [2A](#F2){ref-type="fig"}.

![Analysis of rearrangement detection performance by the Tempus pipeline and retrospective analysis of recurrent fusions\
(**A**) Fusions detected by cancer type. (**B**) Positive control fusion samples (*ROS1-SLC34A2*) processed by the xT assay over the course of 4 months. The fusion was expected at 5% VAF in the control and was consistently detected across flow cells and instruments. (**C**) Limit of detection analysis for two serially diluted fusions (*ALK-EML4* and *RET-ANKRD26*). Both fusions were detected down to 3--5% simulated VAF by the Tempus xT Assay. (**D**) Functional characterization of fusions detected by the xT assay. Domains, regions, and sites are highlighted for orientation along the amino acid sequence for each protein involved in the rearrangement event. (**E**) Analysis of the recurrent *TMPRSS2-ERG* fusion found in 13 prostate cancers detected by the xT assay. The xT assay consistently localized breakpoints to the expected functional domains resulting in the *TMPRSS2* promoter and replacing the first several exons of *ERG* by a chromosomal deletion. This results in the functional domains of *ERG* being largely intact, but under the control of the *TMPRSS2* promoter.](oncotarget-10-2384-g002){#F2}

Specificity was analyzed with a subset of 13 samples that were assessed for the absence of additional xT reportable fusions. This was calculated as the number of samples (*n* = 13) multiplied by the number of assayed genomic sites (*n* = 21) for 273 positions. The xT assay called zero false positive translocations, resulting in a \>99.9% specificity. Furthermore, a positive control fusion monitored by Tempus (*ROS1-SLC34A2*) in the reference standard (HD753, Horizon Diagnostics) was detected 20 out of 20 times (Figure [2B](#F2){ref-type="fig"}).

To assess the LOD, we used a serial dilution of two known positive control samples (containing *ALK-EML4* and *ANKRD26-RET*, respectively). Samples were diluted from 50-60% VAF in the primary sample to 3-4% VAF (Figure [2C](#F2){ref-type="fig"}). The gene rearrangements were detected in all experiments, but in the case of the two lowest titrations for *ALK-EML4*, the number of supporting reads fell below the normal reporting threshold for the assay. A conservative LOD was set at 10% based on the *ALK-EML4* detection data. Additionally, we functionally characterized clinically relevant fusions detected via the xT assay, such as *RET-CCDC6* and *TMPRSS2-ERG* fusions (Figure [2D, 2E](#F2){ref-type="fig"}).

Copy number alterations {#s2_3}
-----------------------

Copy number variation (CNV) is particularly difficult to detect in targeted panels. Paired-end mapping strategies typically fail because the majority of CNV breakpoints occur in non-targeted regions \[[@R20]\]. The depth of coverage is the primary metric used to determine copy number, but variable probe affinities, probe balance, and hybridization produce significant coverage variability \[[@R21]\]. This can be corrected by comparing the tumor sample with its matched normal sample and/or a pool of unrelated normal samples. The xT panel design significantly reduces the number of heterozygous SNVs required to make an integrated segmentation call. Accordingly, models used for fitting corrected coverage ratios to potential ploidy and corresponding copy number are selected based not only on goodness-of-fit but also on the resulting genome-wide ploidy state \[[@R22]\]. CNV specificity was assessed as the total number of genes assayed (*n* = 67 patients, 39 genes each) and the number of false positive detections (*n* = 3). Specificity was calculated as called negatives/true negatives, resulting in a final specificity of 99.8%. PPV was calculated as the total number of amplification calls made by the xT copy number analysis pipeline (*n* = 70) versus the number of copy number calls that were correctly identified as amplified (*n* = 67). This latter analysis was performed using CNVs that were clearly amplified in xO (\>9 copies), or those identified as amplified in xT, but moderately amplified (\>5 copies) in xO. This resulted in a final PPV of 95.7%. To assess LOD, three samples with CNVs in *ERBB2, CDK12,* or *EGFR* were diluted between 50% and 5% tumor purity. In all cases, amplified regions were detected and identified as amplified down to at least 12.5% tumor purity. To allow for the detection of less-heavily amplified genetic regions, a lower LOD was set at 30% tumor purity.

Additionally, the National Institutes of Standards and Technology\'s (NIST) RM 2373 (Genomic DNA Standards for HER2 Measurements) was evaluated for CNVs in *ERBB2* (HER2). The copy number results for *ERBB2* generated by the xT assay were linear (r^2^=0.97) with respect to the validated copy ratios across the five reference samples (Figure [3A](#F3){ref-type="fig"}). Furthermore, the amplification call crosses the regression line at an *ERBB2* ratio of 2.5. In calling *ERBB2* positivity in breast cancers using FISH, an *ERBB2* ratio of 2.2 was used to call positivity, closely correlating with the assay threshold for amplification calling. The distribution of CNVs by cancer type for the patient cohort sequenced at Tempus Labs is shown in Figure [3B](#F3){ref-type="fig"}.

![Analysis of performance of the xT assay in the detection of copy number variations\
(**A**) Detection comparison of Tempus copy number calls against validated *ERBB2* control ratios. (**B**) Plot of reported CNVs by cancer type for the xT patient cohort sequenced at Tempus. (**C**) A representative 1p-19q co-deletion detected commonly in oligodendrogliomas. The blue dots represent genomic regions showing one copy loss while the grey points represent neutral segments.](oncotarget-10-2384-g003){#F3}

Finally, large scale genomic alterations were assessed using the xT assay (Figure [3C](#F3){ref-type="fig"}). Due to the long-range genomic tiling of the xT assay, it was hypothesized that large scale genomic instability might be detectable via chromosome level copy number visualization. For example, in oligodendrogliomas, the xT assay consistently detected the 1p-19q co-deletion, an important diagnostic and prognostic marker. These complex structural alterations were successfully detected with the xT assay although they are not part of the common class of focal alterations reported in the literature from NGS-based tumor profiling methodologies.

Microsatellite instability detection {#s2_4}
------------------------------------

MSI results from defects in DNA mismatch repair. To validate MSI status determination and evaluate the accuracy of the test, we analyzed samples from 34 patients (14 microsatellite instability-high \[MSI-H\], 20 microsatellite stable \[MSS\]). For three MSI-H patients, an additional four samples were generated for LOD testing with a two-fold serial dilution. For two additional MSI-H patients, three replicates were sequenced on the same plate for intra-assay precision and three replicates were sequenced on separate plates for inter-assay precision. The accuracy, precision, and LOD were assayed for tumor-normal paired and tumor-only samples.

The xT MSI assay was validated against an MSI PCR assay using the five marker Bethesda panel (Arup Laboratories, Salt Lake City, UT), a four-protein MMR immunohistochemistry (IHC) panel (Tempus Labs, Chicago, IL), or both. Samples found to be MSI-H by the MSI PCR, or missing expression in at least one protein by the MMR IHC were collectively considered MSI-H. Similarly, samples found to be MSS by the MSI PCR, or with normal MMR protein expression by the MMR IHC were considered MSS. One sample had contradictory MSI PCR and MMR IHC results and was removed from the study. In both paired and unpaired modes, the 14 MSI-H samples were correctly classified as MSI-H and the 20 MSS samples were correctly classified as MSS, thus, the sensitivity of MSI status determination was \>99%, the specificity was \>99%, and the PPV was \>99%.

To establish the LOD, three MSI-H patient DNA samples were serially diluted to determine the minimum tumor fraction necessary to reliably detect MSI-H status. MSI-H status was consistently detected down to approximately 20% tumor in both the paired and unpaired modes. The LOD was conservatively set at 30% tumor.

Immuno-oncology profiling {#s2_5}
-------------------------

Immunotherapy has become a key tool for treating a wide range of cancers. A current challenge in the field is the proper identification of patients most likely to benefit from this powerful but expensive therapy that can also have severe side effects \[[@R25]--[@R28]\]. In the course of clinical care, TMB, Human Leukocyte Antigen (HLA) type, neoantigen load, and MSI status were calculated in order to evaluate the benefits of immunotherapy. HLA genes are involved in the presentation of self- and foreign peptides to T cells. Specific HLA alleles are associated with serious pharmacological counter-indications, eligibility for clinical trials, and increased probability of response or non-response to checkpoint therapy. HLA typing is also a prerequisite for neoantigen prediction. We assessed the accuracy and sensitivity of *in silico* HLA typing on a set of 72 known reference samples obtained directly from the International Histocompatibility Working Group in Seattle, WA ([www.ihwg.org](http://www.ihwg.org)). For reference samples sequenced on the xT panel, class I HLA typing was 99.8% accurate at the two-digit resolution and 96.6% accurate at the four-digit resolution ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Sequencing was also sensitive for alleles associated with pharmacological counter-indications and alleles used for inclusion and exclusion criteria in immunotherapy clinical trials ([Supplementary Tables 2--3](#SD1){ref-type="supplementary-material"}).

TMB and MSI status was assessed in 806 clinical samples spanning more than 28 different cancer types (Figure [4](#F4){ref-type="fig"}). While predictive power varied with cancer type, the xT assay TMB scoring recapitulated disease-specific TMB estimates previously reported in the literature \[[@R29]\] (Figure [4A](#F4){ref-type="fig"}). One of the most well characterized mechanistic drivers of high TMB is MSI-H status. The xT MSI assay showed that MSI-H tumors accounted for 26.6% of tumors in the top decile of TMB, with MSI-H status significantly associated with high TMB (*p* = 8.72e--26, hypergeometric test). In MSI-H cases, alterations were frequently found in genes encoding DNA mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6). In a number of cases where no genetic alterations were found, we were able to detect MLH1 silencing based on reduced RNA expression. The assay also detected an enrichment of alterations in known DNA repair genes, including *WRN, RAD50, PMS1, MUTYH, BRCA1, BRCA2, BLM,* and *ATM* (Figure [4B](#F4){ref-type="fig"}).

![Survey of immunotherapy markers across diverse cancer types\
(**A**) The distribution of TMB for each cancer type plotted on a log2 scale and ordered by the median TMB. Outliers (data points beyond 1.5x interquartile range) are shown as individual points. (**B**) Analysis of samples in the top 10th percentile of TMB. The inset shows the distribution of TMB across all samples included in the study, with the vertical bar marking the 90th percentile of TMB. The bar chart shows the proportion of predicted antigenic mutations of the non-synonymous mutations detected. MSI-H samples are highlighted in red. The color-coded matrices show the MMR gene mutations detected by mutation type (top), predicted MLH1 methylation status (middle), and DNA repair gene mutations detected (bottom).](oncotarget-10-2384-g004){#F4}

Pan-cancer molecular profiling {#s2_6}
------------------------------

We next analyzed the landscape of genomic alterations in 1074 clinical samples assayed with the xT panel. A subset of samples was optimized to appropriately represent the percentages of cancer types seen in clinical care sites serviced by Tempus Labs. These data were then compared against large-scale genomic profiling efforts \[[@R23], [@R24]\] to assess the clinical validity of the assay. Within the Tempus cohort, 952 samples contained at least one biologically relevant alteration (88.6%), which was defined as an alteration associated with pathogenicity based on literature, databases, or *in silico* reviews. The evidence for biological relevance ranges from alterations addressed by the National Comprehensive Cancer Network (NCCN) guidelines with FDA-approved therapeutic interventions, through on and off tissue clinical research, down to preclinical evidence with or without clinical trial eligibility. Within the 952 patients, the most prevalent alterations across cancer types were the tumor suppressor *TP53* (57%) and the oncogene *KRAS* (20%) (Figure [5A](#F5){ref-type="fig"}). Along with these highly prevalent alterations known to be present in an array of cancer types, there were many canonical oncogenic pathway mutations detected, including gain of function mutations in oncogenes (*EGFR* 11%, *PIK3CA* 16%) and loss of function mutations in tumor suppressor genes (*PTEN* 11%, *ARID1A* 8%, *APC* 6%) \[[@R37], [@R38], [@R41]\]. Furthermore, the localization of variants in recurrently mutated genes showed a strong correlation across cancer types (Figure [5B](#F5){ref-type="fig"}), indicating consistent functional mechanisms for oncogenicity as expected from previous pan-cancer studies \[[@R24]\].

![Mutational landscape across all cancer types\
(**A**) Plot of a subset of patients within the Tempus xT cohort containing at least one biologically relevant alteration, stratified by alteration prevalence. Patients were clustered by the mutational profile similarity of genes (y-axis) with at least 5 actionable alterations detected within the cohort. Patient cancer type is displayed by the colored bar below the matrix. (**B**) Lollipop plot of *TP53, KRAS*, and *PIK3CA* alterations detected by the xT assay across all cancer types.](oncotarget-10-2384-g005){#F5}

DISCUSSION {#s3}
==========

Molecularly targeted therapies, including immunotherapy, are providing better treatment options for cancer patients. To fully utilize these advances, patients must undergo broad molecular tumor profiling for optimal, personalized treatment selection \[[@R1]\]. According to NCCN guidelines, therapy targeted towards specific molecular alterations is already a standard of care in several tumor types, including melanoma, colorectal cancer, and non-small cell lung cancer. These few, well-known mutations could be detected with individual assays or small NGS panels. However, for the largest number of patients to benefit from personalized oncology, molecular alterations that can be targeted with off-label drug indications, combination therapy, or tissue agnostic immunotherapy should be assessed \[[@R30]--[@R32]\]. Large-panel NGS assays also cast a wider net for clinical trial enrollment \[[@R33], [@R34]\]. Recent studies indicate that clinical care is guided by NGS assay results for 30-40% of patients who receive such testing \[[@R35]--[@R38]\].

We have developed a hybrid capture NGS-based assay to accurately detect clinically relevant alterations across 595 genes that are carefully curated to address solid tumors and hematologic malignancies, plus perform genome-wide unbiased fusion detection. The assay inputs include FFPE tissue, blood or bone marrow tumor specimens, and blood or saliva for germline testing. This assay is unique in its use of matched tumor and normal DNA plus whole transcriptome RNA-seq to provide a comprehensive overview of somatic genomic alterations, including MSI status for targeted cancer therapy, immuno-oncology, and clinical trial enrollment. The test was validated by multiple testing modalities, including a comparison of patient samples to reference assays and pooled cell-line models spanning key determinants of detection accuracy for somatic alterations such as VAF, indel length, the degree of stromal admixture, and amplitude of CNV.

Large NGS panels optimize targeted therapy options because they reveal a wide range of genomic alterations and can be used when working with small FFPE tissue samples. Additionally, broad-based NGS genomic profiling enables patients with rare genomic alterations to be identified for clinical trials. The Tempus xT assay provides the opportunity to deep screen known actionable gene variants and a broad set of biologically relevant cancer-related genes on a clinically validated platform with a relatively rapid turnaround time.

MATERIALS AND METHODS {#s4}
=====================

xT assay gene selection {#s4_1}
-----------------------

Genes were selected for the xT assay based on recommendations from major professional oncology-related societies, including the National Comprehensive Cancer Network (NCCN), the Association for Molecular Pathology (AMP), the College of American Pathologists (CAP), and the American College of Medical Genetics and Genomics (ACMG). An extensive literature review was conducted to include the addition of genes from known oncogenic pathways, particularly those covered in The Cancer Genome Atlas (TCGA) analysis of oncogenic signaling pathways \[[@R41]\]. In this publication, 89% of the 9,125 tumors analyzed contained at least one driver alteration in one of the 10 canonical pathways. Thus, these genes alone account for a substantial number of driver mutations across cancer types. Next, genes from DNA repair, chromatin remodeling, splicing, ubiquitination, and metabolic pathways were included in the assay. Genes associated with treatment resistance and cancer predisposition, including all cancer-associated genes listed as incidental findings by the ACMG, were also included. Additionally, the intronic regions of 21 key genes that undergo clinically relevant gene rearrangements were included for robust fusion detection. Finally, the gene list was reviewed for completeness by experts familiar with the literature and current medical practices for all major tumor types.

Sample processing and nucleic acid extraction {#s4_2}
---------------------------------------------

A total of 265 patient samples were processed and used in the validation of this study. Normal blood samples were collected in PAXgene Blood DNA Tubes (Catalog \#761115) and saliva samples were collected in Oragene DNA Saliva Kits (Catalog \#OG-510). Germline ("normal") DNA was extracted from either 650μl of saliva or 200 μl of blood. After expert pathologist assessment of overall tumor amount and percent tumor cellularity as a ratio of tumor to normal nuclei met a 20% threshold, solid tumor total nucleic acid was extracted from macrodissected FFPE tissue sections and digested by proteinase K. RNA was purified from the total nucleic acid by DNase-I digestion.

Hematologic malignancy samples were collected in EDTA collection tubes. We examined a set of samples collected at Rush University Medical Center (RUMC) that were also analyzed with a Genoptix Myeloid Molecular Panel (Carlsbad, CA) at RUMC. A subset of samples was also sent to Mayo Medical Laboratories (Rochester, MN) for additional testing with a 33 gene hematologic profiling panel.

DNA and RNA library construction and sequencing {#s4_3}
-----------------------------------------------

DNA and RNA sequencing was performed as previously described \[[@R8]\]. Briefly, 100 nanograms (ng) of DNA for each tumor and normal sample was mechanically sheared to an average size of 200 base pairs (bp) using a Covaris ultrasonicator. DNA libraries were prepared using the KAPA Hyper Prep Kit, hybridized to the xT probe set, and amplified with the KAPA HiFi HotStart ReadyMix. One hundred ng of RNA for each tumor sample was heat fragmented in the presence of magnesium to an average size of 200 bp. Library preps were hybridized with the IDT xGEN Exome Research Panel and target recovery was performed using Streptavidin-coated beads, followed by amplification with the KAPA HiFi Library Amplification Kit. The amplified target-captured DNA tumor libraries were sequenced to an average unique on target depth of 500x on an Illumina HiSeq 4000. Samples were further assessed for uniformity with each sample required to have 95% of all targeted bp sequenced to a minimum depth of 300x.

Detection of somatic variants by the xT assay {#s4_4}
---------------------------------------------

Tumor and normal FASTQ files were matched to their appropriate pair. FASTQ files were analyzed using FASTQC for rapid assessment of quality control and aligned with Novoalign (Novocraft, Inc.). The SAM files were converted to BAM, BAM files were sorted, and duplicates were marked. Following alignment and sorting, SNVs were called. To assess copy number, de-duplicated BAM files and a VCF generated from the variant calling pipeline were processed for computation of read depth and variation in heterozygous germline SNVs between the tumor and normal samples (or between the tumor sample and a pool of process matched normal controls for tumor-only cases). Circular binary segmentation \[[@R9]\] was applied and segments were selected with highly differential log2 ratios between the tumor and its comparator. Approximate integer copy number was then assessed from a combination of differential coverage in segmented regions and an estimate of stromal admixture generated by analysis of heterozygous germline SNVs.

Detection and visualization of gene rearrangements by the xT assay {#s4_5}
------------------------------------------------------------------

Following de-multiplexing, tumor FASTQ files were aligned against the human reference genome using BWA for DNA files, or aligned to GRCh38 using STAR for RNA files \[[@R10], [@R39]\]. Raw RNA read counts were then normalized to correct for GC content and gene length using full quantile normalization and adjusted for sequencing depth via the size factor method. DNA reads were sorted and duplicates were marked with SAMBlaster \[[@R40]\]. Discordant and split reads were further identified and separated. These data were then read into LUMPY \[[@R11]\] for structural variant detection. Structural alterations were grouped by type, recurrence, and presence within the Tempus database and displayed through the Tempus quality control application (TSQC) fusion tool. The TSQC fusion viewer referenced Ensembl to determine the gene and proximal exons surrounding the breakpoint for any possible transcript generated across the breakpoint. It then placed the breakpoint 5′ or 3′ to the subsequent exon in the direction of transcription. For inversions, this orientation was reversed for the inverted gene. After positioning of the breakpoint, the translated amino acid sequences were generated for both genes in the chimeric protein, and a plot was generated containing the remaining functional domains for each as returned from Uniprot \[[@R12]\] (Figure [2D, 2E](#F2){ref-type="fig"}).

Variant classification and reporting {#s4_6}
------------------------------------

Variants were investigated following criteria from known evolutionary models, functional data, clinical data, and literature. Variants were then prioritized and classified based on known gene-disease relationships, hotspot regions within genes, internal and external somatic databases, primary literature, and other features of somatic drivers \[[@R13], [@R14], [@R15]\]. Variants were reported based on recommendations from the AMP/ASCO/CAP guidelines \[[@R16]\]. Briefly, pathogenic variants with therapeutic, diagnostic, or prognostic significance were prioritized in the report. Non-actionable pathogenic variants were included as biologically relevant, followed by variants of uncertain significance. Translocations were reported based on features of known gene fusions, relevant breakpoints, and biological relevance. Evidence was curated from outside sources and presented as 1) consensus guidelines 2) clinical research, or 3) case studies, with a link to the supporting literature. Germline alterations were reported as secondary findings in a subset of genes for consenting patients. These include genes recommended by the ACMG \[[@R17]\] and additional genes associated with cancer predisposition or drug resistance.

Microsatellite instability status {#s4_7}
---------------------------------

We developed probes for 43 microsatellite regions for the xT assay. The MSI classification algorithm classifies tumors into three categories: microsatellite instability-high (MSI-H), microsatellite stable (MSS), or microsatellite equivocal (MSE). MSI testing for paired tumor-normal patients used reads mapped to the microsatellite loci with at least five bp flanking the microsatellite. The identification of at least 30 mapping reads in both tumor and normal samples were required for the locus to be included in the analysis. At least 20 of the 43 microsatellites on the panel were required to reach the minimum coverage. Each locus was individually tested for instability, as measured by changes in the number of repeats in tumor data compared to normal data, using the Kolmogorov-Smirnov test. If *p* ≤ 0.05, the locus was considered unstable. The proportion of unstable microsatellite loci was fed into a logistic regression classifier trained on samples from the TCGA colorectal and endometrial cohorts, which have clinically determined MSI statuses. For MSI testing in tumor-only mode, the mean and variance for the number of repeats were calculated for each microsatellite locus. A vector containing the mean and variance data was put into a support vector machine classification algorithm. Both algorithms returned the probability of the patient being MSI-H. If there was a \>70% probability of MSI-H status, the sample was classified as MSI-H. If there was between a 30-70% probability of MSI-H status, the test results were too ambiguous to interpret and those samples were classified as MSE. If there was a \<30% probability of MSI-H status, the sample was considered MSS.

Tumor mutational burden {#s4_8}
-----------------------

TMB was calculated by dividing the number of non-synonymous mutations by the megabase size of the panel (2.4 MB). All non-silent somatic coding mutations, including missense, indel, and stop-loss variants, with coverage \>100x and an allelic fraction \>5% were counted as non-synonymous mutations. A TMB \>9 mutations per million bp of DNA was considered "high". This threshold was established by hypergeometric testing for the enrichment of tumors with orthogonally defined hypermutation (MSI-H) in the larger Tempus clinical database.

HLA typing {#s4_9}
----------

HLA class I typing was performed using Optitype on DNA sequencing including class I HLA-mapped reads and unmapped reads \[[@R18]\]. Normal samples were used as the default reference for matched tumor-normal samples. Tumor sample-determined HLA type was used when the normal sample did not meet internal HLA coverage thresholds, or there was no matched normal sample.

Neoantigen prediction {#s4_10}
---------------------

Neoantigen prediction was performed on all non-silent mutations. The binding affinities for all possible 8-11 amino acid (aa) peptides containing the mutation were predicted using MHCflurry \[[@R19]\]. For alleles with insufficient training data to generate an allele-specific MHCflurry model, binding affinities were predicted from the nearest HLA allele as assessed by aa homology. A mutation was determined to be antigenic if any resulting peptide was predicted to bind to any of the patient\'s HLA alleles with \<500 nM affinity.
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